Literature DB >> 1415694

Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide.

R J Playford1, M A Benito-Orfila, P Nihoyannopoulos, K A Nandha, J Cockcroft, S Todd, M A Ghatei, J Domin, S R Bloom, J Calam.   

Abstract

Peptide YY (PYY) reverses the increased intestinal secretion stimulated by vasoactive intestinal peptide (VIP) in humans. VIP also dilates blood vessels, so we investigated the effect of PYY on the cardiovascular system. Six volunteers received PYY, 0.4 and 1.2 pmol.kg-1 x min-1 i.v. for 2 h, reproducing plasma levels seen postprandially and during a diarrheal illness, respectively. Cardiac function was assessed by echocardiography. PYY infused at 0.4 pmol.kg-1 x min-1 had no effect on cardiovascular parameters. PYY infused at 1.2 pmol.kg-1 x min-1 caused a fall in both stroke volume from 128 +/- 8 to 110 +/- 8 ml/beat (mean +/- 95 confidence interval, P < 0.01) and cardiac output from 7.2 +/- 0.4 to 6.1 +/- 0.4 l/min (P < 0.01). Effects of infusion of PYY into the brachial artery at doses of 0-16 pmol/min were assessed using venous occlusion plethysmography in six subjects. PYY infusion caused a dose-dependent fall in forearm blood flow. Six subjects received VIP, 5 pmol.kg-1 x min-1 i.v., causing a rise in heart rate from 55 +/- 3 to 70 +/- 3 beats/min and increased cardiac output from 7.3 +/- 1.1 to 13.1 +/- 1.1 l/min. The addition of PYY, 0.4 pmol.kg-1 x min-1 i.v., did not affect the heart rate significantly but decreased the cardiac output to 10.4 +/- 1.1 l/min (P < 0.01). Infusions of PYY into the brachial artery at 5 pmol/min decreased local vasodilation induced by VIP infused at 2 pmol/min at the same site by 40% (P < 0.01), even though this dose of PYY had no significant effect on local blood flow when given alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415694     DOI: 10.1152/ajpendo.1992.263.4.E740

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY.

Authors:  S Unniappan; C H S McIntosh; H-U Demuth; U Heiser; R Wolf; T J Kieffer
Journal:  Diabetologia       Date:  2006-06-27       Impact factor: 10.122

Review 2.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

3.  Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes.

Authors:  Manish Suneja; Daryl J Murry; John B Stokes; Victoria S Lim
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-19       Impact factor: 4.310

4.  Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans?

Authors:  Jutta Keller; Jan C Mueller-Wolf; Keihan Ahmadi-Simab; Christiane Fibbe; Ulrich Rosien; Peter Layer
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

5.  Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses.

Authors:  Sofia Bouhlal; Kayla N Ellefsen; Mikela B Sheskier; Erick Singley; Sandrine Pirard; David A Gorelick; Marilyn A Huestis; Lorenzo Leggio
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

6.  Brain neuropeptides in central ventilatory and cardiovascular regulation in trout.

Authors:  Jean-Claude Le Mével; Frédéric Lancien; Nagi Mimassi; J Michael Conlon
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-30       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.